{
  "docId": "019de517-44b3-71b5-8a8d-243b41bb1797",
  "docSlug": "c77cf9536b998c2f906519be4212f807",
  "documentTitle": "GH Research | Investor Presentation Deck | 30 slides",
  "authorId": "gh-research",
  "authorName": "GH Research",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 30,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 20,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de517-44b3-71b5-8a8d-243b41bb1797/16",
  "deckHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797",
  "deckJsonHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797.json",
  "deckAnchorHref": "/decks/019de517-44b3-71b5-8a8d-243b41bb1797#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.545,
        "w": 0.3692,
        "x": 0.0892,
        "y": 0.2125
      },
      "kind": "list",
      "text": "Study Safety Group review\nNo SAEs\nAll ADRs mild, except three moderate*\nAll ADRs resolved spontaneously\nInhalation well-tolerated\nNo noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001\nNo clinically significant changes in safety laboratory analyses, psychiatric safety assessments or measures of cognitive function\nNo safety signal relating to suicidal ideation or suicidal behavior, based on C-SSRS and MADRS subscore item \"suicidal thoughts\"",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "600f8241-ae07-4880-bd13-3576bcc51602",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.0167,
        "w": 0.125,
        "x": 0.815,
        "y": 0.8833
      },
      "kind": "source-note",
      "text": "16-12 mg (n=6); 6-12-18 mg (n=2)",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b4ad705b-4df3-4a99-9aa3-e8692b19599c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.595,
        "x": 0.0692,
        "y": 0.875
      },
      "kind": "source-note",
      "text": "SAE, Serious Adverse Event; ADR, Adverse Drug Reaction, an adverse event with a relationship code to the investigational product of definite, probable, or possible, or where code is missing; IDR, Individualized Dosing Regimen; C-SSRS, Columbia-Suicide Severity Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2255054-d7e9-429c-b1e6-90ac647337ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.515,
        "w": 0.5283,
        "x": 0.4167,
        "y": 0.2042
      },
      "kind": "table",
      "text": "ADRS, MedDRA Preferred Term, Phase 1 (Single Dose), 12 mg (n=4), 18 mg (n=4), Phase 2 (IDR), IDR1 (n=8), Number of Events, Abdominal discomfort, 1, Anxiety, 2, Depressive symptom, 1*, Dizziness, 1, Feeling abnormal, 1, 1, Flashback, 1, 2, Headache, 2, 1, 3, Muscle discomfort, 1, Muscle spasms, 1, Nausea, 2*, Paresthesia, 1, Sensory disturbance, 3",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07810e49-af57-4cdf-ab02-8fc1da1cc0ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.0517,
        "w": 0.7442,
        "x": 0.0708,
        "y": 0.1025
      },
      "kind": "title",
      "text": "Phase 1 (Single Dose) and Phase 2 (IDR) – Safety",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "356e7516-9a37-424c-b1ab-c469be9a2054",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "e59b812c-5781-40d1-880d-5eb666da502e",
      "evidence": "The document emphasizes the limitations of current treatments and the potential of GH001",
      "position": 0,
      "objective": "Highlight the need for more effective depression treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "a0a779b4-6b2d-4f03-ae8f-5683cc3e54fa",
      "evidence": "The document presents a clear 'why' for GH001, highlighting its potential to provide ultra-rapid, durable remissions",
      "position": 1,
      "objective": "Explain why GH001 is a necessary solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}